EA200200890A1 - Применение ингибиторов il-18 - Google Patents

Применение ингибиторов il-18

Info

Publication number
EA200200890A1
EA200200890A1 EA200200890A EA200200890A EA200200890A1 EA 200200890 A1 EA200200890 A1 EA 200200890A1 EA 200200890 A EA200200890 A EA 200200890A EA 200200890 A EA200200890 A EA 200200890A EA 200200890 A1 EA200200890 A1 EA 200200890A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
medicament
prevention
manufacture
treatment
Prior art date
Application number
EA200200890A
Other languages
English (en)
Other versions
EA005583B1 (ru
Inventor
Йоланд Шватшко
Чарльз Динарелло
Кристин Платер-Зиберк
Сантер Ван Девентер
Менахем Рубинштейн
Даниэла Новик
Соо-Хиун Ким
Original Assignee
Апплайд Резеч Системз Арс Холдинг Н.В.
Йеда Рисерч Энд Дивелопмент Компани Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Апплайд Резеч Системз Арс Холдинг Н.В., Йеда Рисерч Энд Дивелопмент Компани Лтд. filed Critical Апплайд Резеч Системз Арс Холдинг Н.В.
Publication of EA200200890A1 publication Critical patent/EA200200890A1/ru
Publication of EA005583B1 publication Critical patent/EA005583B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Изобретение относится к применению ингибиторов IL-18 при получении лекарственного средства для лечения и/или предупреждения повреждения печени. Изобретение также относится к применению ингибиторов IL-18 при получении лекарственного средства для лечения и/или предупреждения артрита, в частности ревматоидного артрита. Кроме того, изобретение относится к применению ингибиторов IL-18 при получении лекарственного средства для лечения и/или предупреждения воспалительного заболевания кишечника, в частности болезни Крона или неспецифического язвенного колита.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200890A 2000-02-21 2001-02-20 Применение ингибиторов il-18 EA005583B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00103590 2000-02-21
EP00103597 2000-02-21
EP00121651 2000-10-04
EP00125633 2000-11-23
PCT/EP2001/001867 WO2001062285A1 (en) 2000-02-21 2001-02-20 Use of il-18 inhibitors

Publications (2)

Publication Number Publication Date
EA200200890A1 true EA200200890A1 (ru) 2003-02-27
EA005583B1 EA005583B1 (ru) 2005-04-28

Family

ID=27439934

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200890A EA005583B1 (ru) 2000-02-21 2001-02-20 Применение ингибиторов il-18

Country Status (31)

Country Link
US (1) US20030157094A1 (ru)
EP (1) EP1257292B1 (ru)
JP (1) JP4744763B2 (ru)
KR (3) KR20070087256A (ru)
CN (1) CN1322897C (ru)
AT (1) ATE506959T1 (ru)
AU (2) AU2001240636B8 (ru)
BG (1) BG66134B1 (ru)
BR (1) BR0108514A (ru)
CA (2) CA2683009C (ru)
CY (1) CY1111687T1 (ru)
CZ (1) CZ304485B6 (ru)
DE (1) DE60144514D1 (ru)
DK (1) DK1257292T3 (ru)
EA (1) EA005583B1 (ru)
EE (1) EE05423B1 (ru)
HK (1) HK1051965A1 (ru)
HR (1) HRP20020652A2 (ru)
HU (1) HU227752B1 (ru)
IL (2) IL151388A0 (ru)
ME (1) ME00546B (ru)
MX (1) MXPA02008079A (ru)
NO (1) NO331971B1 (ru)
NZ (3) NZ535299A (ru)
PL (1) PL206549B1 (ru)
PT (1) PT1257292E (ru)
RS (1) RS51737B (ru)
SI (1) SI1257292T1 (ru)
SK (1) SK288032B6 (ru)
TR (2) TR200502508T2 (ru)
WO (1) WO2001062285A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1257585A2 (en) * 2000-02-10 2002-11-20 Basf Aktiengesellschaft Antibodies that bind human interleukin-18 and methods of making and using
SK288032B6 (sk) * 2000-02-21 2012-12-03 Merck Serono Sa Use of IL-18 inhibitors for manufacture of medicament for treatment and/or prevention of alcoholic hepatitis
AU1174402A (en) 2000-10-11 2002-04-22 Viron Therapeutics Inc Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
ES2334773T3 (es) * 2001-05-16 2010-03-16 Yeda Research And Development Co. Ltd. Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis.
AU2002341321A1 (en) * 2001-11-30 2003-06-10 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
CA2513584A1 (en) * 2003-01-20 2004-08-05 Vib Vzw The use of yop proteins or rho gtpase inhibitors as caspase-1 inhibitors
CA2523912A1 (en) 2003-04-30 2004-11-11 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
WO2005047906A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring il-18
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
EP2177907B1 (en) 2004-06-30 2014-01-01 Atsuo Sekiyama Indicator agent for noninflammatory stress response and use therefor
JP5595632B2 (ja) 2004-07-16 2014-09-24 敦生 関山 Ｉｌ−１８レセプターアンタゴニスト、および当該アンタゴニストを含む薬学的組成物
PL1885753T3 (pl) 2005-06-03 2011-12-30 Ares Trading Sa Wytwarzanie rekombinowanego białka wiążącego IL-18
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
EP1746167A1 (en) * 2005-07-20 2007-01-24 Apoxis SA Method for the identification of compounds susceptible to inhibit inflammation
TWI422387B (zh) 2006-05-25 2014-01-11 Glaxo Group Ltd 免疫球蛋白
US8440195B2 (en) * 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
GB201213968D0 (en) * 2012-08-06 2012-09-19 Isis Innovation Prevention and treatment of osteoarthritis
AU2014317035B2 (en) 2013-09-05 2020-02-27 Ab2 Bio Sa IL-18 binding protein (IL-18BP) in inflammatory diseases
CN107660150B (zh) 2015-03-05 2023-10-24 Ab2生物股份有限公司 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
CN106109497A (zh) * 2016-07-25 2016-11-16 深圳爱生再生医学科技有限公司 治疗肝硬化的干细胞制剂
CN106834449B (zh) * 2017-01-10 2019-04-30 东南大学 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用
US20210115131A1 (en) * 2018-06-14 2021-04-22 Université De Bordeaux Treatment of Placental Chronic Histiocytic Intervillositis Using an Inhibitor of Interleukin-1
JPWO2023286694A1 (ru) 2021-07-13 2023-01-19
CN117647645B (zh) * 2024-01-29 2024-04-12 中国人民解放军总医院第一医学中心 Lbp、atf6、m-csfr联用在制备诊断自身免疫性肝病产品中的应用及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
PT936923E (pt) * 1996-11-15 2004-04-30 Kennedy Inst Of Rheumatology Supressao de tnfalfa e il-12 em terapia
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
JP4026923B2 (ja) * 1997-03-12 2007-12-26 株式会社林原生物化学研究所 ポリペプチド
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
WO2000012555A1 (fr) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Proteine de liaison de l'interleukine 18
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
EP1257585A2 (en) * 2000-02-10 2002-11-20 Basf Aktiengesellschaft Antibodies that bind human interleukin-18 and methods of making and using
SK288032B6 (sk) * 2000-02-21 2012-12-03 Merck Serono Sa Use of IL-18 inhibitors for manufacture of medicament for treatment and/or prevention of alcoholic hepatitis
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
CA2683009C (en) 2014-09-23
AU4063601A (en) 2001-09-03
EE05423B1 (et) 2011-06-15
CN1404400A (zh) 2003-03-19
NZ520122A (en) 2005-04-29
HUP0300061A3 (en) 2005-09-28
PL357554A1 (en) 2004-07-26
KR20070087256A (ko) 2007-08-27
ATE506959T1 (de) 2011-05-15
EE200200463A (et) 2003-12-15
HRP20020652A2 (en) 2004-12-31
EA005583B1 (ru) 2005-04-28
PT1257292E (pt) 2011-07-05
NO20023962L (no) 2002-08-20
CA2399298C (en) 2014-04-15
BG66134B1 (bg) 2011-06-30
KR20020086540A (ko) 2002-11-18
HK1051965A1 (en) 2003-08-29
AU2001240636B2 (en) 2005-10-13
PL206549B1 (pl) 2010-08-31
RS51737B (sr) 2011-10-31
JP4744763B2 (ja) 2011-08-10
BG107018A (bg) 2003-09-30
US20030157094A1 (en) 2003-08-21
NZ546294A (en) 2008-02-29
CA2399298A1 (en) 2001-08-30
AU2001240636B8 (en) 2005-11-03
NO20023962D0 (no) 2002-08-20
SI1257292T1 (sl) 2011-08-31
NZ535299A (en) 2006-06-30
CY1111687T1 (el) 2015-10-07
MXPA02008079A (es) 2003-02-27
CZ304485B6 (cs) 2014-05-28
EP1257292B1 (en) 2011-04-27
BR0108514A (pt) 2002-12-17
SK288032B6 (sk) 2012-12-03
CA2683009A1 (en) 2001-08-30
IL151388A0 (en) 2003-04-10
WO2001062285A1 (en) 2001-08-30
DE60144514D1 (de) 2011-06-09
EP1257292A1 (en) 2002-11-20
HU227752B1 (en) 2012-02-28
YU60402A (sh) 2005-09-19
HUP0300061A2 (hu) 2003-04-28
ME00546B (me) 2011-10-10
JP2003523403A (ja) 2003-08-05
SK12082002A3 (sk) 2003-05-02
CN1322897C (zh) 2007-06-27
CZ20022843A3 (cs) 2003-02-12
IL151388A (en) 2009-09-01
NO331971B1 (no) 2012-05-14
DK1257292T3 (da) 2011-07-18
TR200202030T2 (tr) 2003-01-21
TR200502508T2 (tr) 2007-04-24
KR20070057282A (ko) 2007-06-04

Similar Documents

Publication Publication Date Title
EA200200890A1 (ru) Применение ингибиторов il-18
DE69907977D1 (de) Pyrrolobenzodiazepine
UA84141C2 (ru) Применение ингибитора пктжк для лечения или профилактики запора
MA27374A1 (fr) Ester de 2'-c-methyl-3'-o-l-valine et de ribofuranosyl cytidine pour le traitement des infections des flaviviridae
ATE425253T1 (de) Tribonektine
EA200401183A1 (ru) Применение ингибиторов il-18 в качестве диагностического маркера
FR2847770B3 (fr) Composition epaississante pour des sauces et produits similaires
EA200200876A1 (ru) Алкилированные производные имидазопиридина
EA200200875A1 (ru) Пролекарства производных имидазопиридина
ATE282411T1 (de) Eisenverbindungen
EA200300844A1 (ru) Использование ингибиторов il-18 для лечения и/или профилактики заболевания сердца
CY1108053T1 (el) Ενωση της κυαμεμαζινης και ενος ατυπου νευροληπτικου
EA200501231A1 (ru) Применение дипиридамола в комбинации с ацетилсалициловой кислотой и антагонистом ангиотензина ii для предупреждения инсульта
EA200300639A1 (ru) Применение sarp-1 для лечения и/или предупреждения склеродермии
EA200200798A1 (ru) Кальцилитические соединения
EA200001140A1 (ru) СОЕДИНЕНИЯ-ИНГИБИТОРЫ sPLA2 ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ
TR200502061T2 (tr) IL-18 inhibitörlerinin kullanımı.
UA38786A (uk) Фібринолітичний засіб
ITSA20020015A1 (it) L'ambigua
ITSA20020011V0 (it) L'ambigua
FI20021275A0 (fi) Terapeuttiset koostumukset käytettäväksi ripulien ehkäisyyn tai hoitoon
FI20001355A0 (fi) Järjestely ympäristön monipuoliseen havainnointiin
ITRM20020006V0 (it) Struttura fotoluminescente per l'individuazione al buio di oggetti edambienti.

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MK4A Patent expired

Designated state(s): RU